RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial

Most women with estrogen receptor expressing breast cancers receiving anti-estrogens such as tamoxifen may not need or benefit from them. Besides the estrogen receptor, there are no predictive biomarkers to help select breast cancer patients for tamoxifen treatment. CCND1 (cyclin D1) gene amplificat...

Full description

Saved in:
Bibliographic Details
Main Authors: Keilty, Dana, Buchanan, Marguerite, Ntapolias, Katerina, Aleynikova, Olga, Tu, Dongsheng, Li, Xiao, Shepherd, Lois, Bramwell, Vivien, Basik, Mark
Format: Artigo
Language:Inglês
Published: Public Library of Science 2013
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3868649/
https://ncbi.nlm.nih.gov/pubmed/24367492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0081740
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items